A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Alogliptin; Pioglitazone

Criteria

Inclusion Criteria:

• Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

• Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion Criteria:

• Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.

• Others who are assessed to be ineligible for the study by the investigator or subinvestigator.